The role of clinicopathological features in the prognosis of resected pancreatic ductal adenocarcinoma: a retrospective study

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies, with a poor overall prognosis and low survival rates. Despite advances in treatment, the five-year survival rate remains dismally low, particularly for patients with advanced disease. Several clinicopathological factors have been associated with survival outcomes; however, their prognostic significance remains debated. Objectives: This study aims to investigate the survival rates of patients with resected PDAC and evaluate the association between clinicopathological characteristics and patient survival outcomes. Patients and Methods: The data of patients diagnosed with PDAC who underwent surgical resection at Tehran Cancer Institute between 2013 and 2019 were retrospectively analyzed. Demographic, clinical, and histopathological characteristics were extracted from medical records and pathology reviews. Patients were followed up to assess their 1- and 3-year survival. Survival analysis was conducted using the Kaplan-Meier method, with comparisons made via the Log Rank test. Cox regression was used for multivariate analysis to assess the association between clinicopathological factors and survival. Results: Thirty-seven patients (56.8% female) with PDAC were included in this study, with a mean age of 59.57 ± 9.24 years. The average tumor size was 3.42 ± 1.19 cm, and 67.5% of tumors were located in the pancreatic head. Lymph node involvement was observed in 67.6% of cases, with vascular and perineural invasion present in 91.9% and 94.6% of patients, respectively. The overall median survival was 15.16 months, with 1-year and 3-year survival rates of 56.8% and 27%, respectively. Univariate analysis showed that diabetes was significantly associated with reduced survival, while multivariate analysis indicated that male gender (hazard ratio [HR] =2.44, 95% confidence interval [CI] = 1.04 to 5.74, P=0.04), underlying diseases (HR =3.54, 95% CI = 1.26 to 9.97, P=0.01), and perineural invasion (HR=34.63, 95% CI =1.04 to 1154.8, P=0.04) were linked to a worse prognosis. Conclusion: In our study, we found that underlying diseases, particularly diabetes, male gender, and perineural invasion, were significantly associated with worse survival in PDAC patients. Despite surgical resection, the median survival was 18 months, with only 1/4 of patients alive at three years. These findings highlight the need for further studies to identify prognostic markers and develop more effective treatment strategies.

Authors

Institutions

Publication Details

Journal
Immunopathologia Persa
Published
2025-02-06
DOI
https://doi.org/10.34172/ipp.2025.43809
Citations
1
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The role of clinicopathological features in the prognosis of resected pancreatic ductal adenocarcinoma: a retrospective study

Masoomeh Safaei, Ali Jafarian, Behnaz Bouzari, Farid Azmoudeh-Ardalan et al.
1 citations
Immunopathologia Persa
Pancreatic and Hepatic Oncology Research
1.05
article

The role of clinicopathological features in the prognosis of resected pancreatic ductal adenocarcinoma: a retrospective study

Masoomeh Safaei, Ali Jafarian, Behnaz Bouzari, Farid Azmoudeh-Ardalan, Nima Taghizadeh Mortezaei, Elham Ebrahimi Niyari
article en
1 citations

Abstract

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies, with a poor overall prognosis and low survival rates. Despite advances in treatment, the five-year survival rate remains dismally low, particularly for patients with advanced disease. Several clinicopathological factors have been associated with survival outcomes; however, their prognostic significance remains debated. Objectives: This study aims to investigate the survival rates of patients with resected PDAC and evaluate the association between clinicopathological characteristics and patient survival outcomes. Patients and Methods: The data of patients diagnosed with PDAC who underwent surgical resection at Tehran Cancer Institute between 2013 and 2019 were retrospectively analyzed. Demographic, clinical, and histopathological characteristics were extracted from medical records and pathology reviews. Patients were followed up to assess their 1- and 3-year survival. Survival analysis was conducted using the Kaplan-Meier method, with comparisons made via the Log Rank test. Cox regression was used for multivariate analysis to assess the association between clinicopathological factors and survival. Results: Thirty-seven patients (56.8% female) with PDAC were included in this study, with a mean age of 59.57 ± 9.24 years. The average tumor size was 3.42 ± 1.19 cm, and 67.5% of tumors were located in the pancreatic head. Lymph node involvement was observed in 67.6% of cases, with vascular and perineural invasion present in 91.9% and 94.6% of patients, respectively. The overall median survival was 15.16 months, with 1-year and 3-year survival rates of 56.8% and 27%, respectively. Univariate analysis showed that diabetes was significantly associated with reduced survival, while multivariate analysis indicated that male gender (hazard ratio [HR] =2.44, 95% confidence interval [CI] = 1.04 to 5.74, P=0.04), underlying diseases (HR =3.54, 95% CI = 1.26 to 9.97, P=0.01), and perineural invasion (HR=34.63, 95% CI =1.04 to 1154.8, P=0.04) were linked to a worse prognosis. Conclusion: In our study, we found that underlying diseases, particularly diabetes, male gender, and perineural invasion, were significantly associated with worse survival in PDAC patients. Despite surgical resection, the median survival was 18 months, with only 1/4 of patients alive at three years. These findings highlight the need for further studies to identify prognostic markers and develop more effective treatment strategies.

Immunopathologia PersaVol. 11
Iran University of Medical Sciences (IR), Imam Khomeini Hospital (IR), Tehran University of Medical Sciences (IR)
Openalex Percentile: Top 24%
Pancreatic and Hepatic Oncology Research
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.